drugset
drugset / Trial / NCT00366600

Study Evaluating HKI-272 Administered to Healthy Subjects

NCT00366600 ↗

Phase 1 Completed 56 enrolled Puma Biotechnology, Inc.
RandomizedSingle-groupOpen-labelTreatment

Summary

Safety and tolerability of HKI-272 in healthy subjects; the influence of food intake on the same.

Timeline

Start
2006-07
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Neratinib Small molecule — Oral

Indications

No indication recorded.